MONTREAL, Jan. 30 /CNW Telbec/ - Sonomax Hearing Healthcare Inc. (TSX
Venture: SHH) announces that Dr. Jeremie Voix, Sonomax's Chief Technology
Officer has been granted a stock option in respect of 400,000 common shares at
an exercise price of $0.04 representing the lowest price of Sonomax shares on
the TSX Venture exchange on January 29th, 2009. The option was granted under
Sonomax's 2001 Stock Option Plan subject to approval by the TSX Venture
"Dr. Voix has been an important member of the Sonomax team since the very
beginning of Sonomax and his science was a key driver behind the SonoPass(TM)
proof of performance software. He will remain a very valuable member of team
Sonomax as we continue to develop leading edge in-ear devices. I am pleased
that Jeremie continues to take a strong leadership role." said Dan Casey, CEO
of Sonomax. Dr. Jérémie Voix obtained his PhD at the Ecole de Technologie
Supérieure in Montreal with a thesis on the "Development of a smart earplug".
Dr. Voix is a Board member of the Canadian Acoustical Association, a Canadian
Member of International Working Group ISO TC43/SC1-WG17 on "Methods of
Measurement of Sound Attenuation of Hearing Protectors" and a member of
Working Group 11 of ANSI Accredited Standards Committee S12, Noise (ANSI
S12/WG11) on "Field Effectiveness and Physical Characteristics of Hearing
Protectors" a His personal quest remains to merge all in-ear devices (aid,
protection, phone, music, etc.) into one "bionic ear"
Sonomax Hearing Healthcare Inc. is a leader in the development and
manufacturing of intra-ear technologies. The company's patented custom-fit,
instant-fit expansion earpieces deliver a perfect acoustic seal every time and
can be certified by SonoPass(R), the company's proprietary, computer generated
proof-of-performance software. Building on its technology leadership in
hearing protection, Sonomax has expanded the applications for its technologies
into high growth consumer products such as MP3 audio, multi-media and gaming
earphones, instant-fit affordable hearing aids, and custom earpieces for
Bluetooth(TM) cellular headsets.
This news release contains certain forward-looking statements that
reflect the current views and/or expectations of Sonomax Hearing Healthcare
Inc. with respect to its performance, business and future events. Such
statements are subject to a number of risks, uncertainties and assumptions.
Actual results and events may vary significantly.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release
For further information:
For further information: Nick Laperle, President, Sonomax Hearing
Healthcare Inc., (514) 932-4432, email@example.com